This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study


Sink, Kaycee M., Leng, Xiaoyan, Williamson, Jeff, Kritchevsky, Stephen B., Yaffe, Kristine, Kuller, Lewis, Yasar, Sevil, Atkinson, Hal, Robbins, Mike, Psaty, Bruce, Goff, David C.


Archives Of Internal Medicine, Volume: 169, No.: 13, Pages.: 1195-1202

Year of Publication



Background: Hypertension (HTN) is a risk factor for dementia, and animal studies suggest that centrally active angiotensin-converting enzyme (ACE) inhibitors (those that cross the blood-brain barrier) may protect against dementia beyond HTN control.; Methods: Participants in the Cardiovascular Health Study Cognition Substudy with treated HTN and no diagnosis of congestive heart failure (n = 1054; mean age, 75 years) were followed up for a median of 6 years to determine whether cumulative exposure to ACE inhibitors (as a class and by central activity), compared with other anti-HTN agents, was associated with a lower risk of incident dementia, cognitive decline (by Modified Mini-Mental State Examination [3MSE]), or incident disability in instrumental activities of daily living (IADLs).; Results: Among 414 participants who were exposed to ACE inhibitors and 640 who were not, there were 158 cases of incident dementia. Compared with other anti-HTN drugs, there was no association between exposure to all ACE inhibitors and risk of dementia (hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.88-1.15), difference in 3MSE scores (-0.32 points per year; P = .15), or odds of disability in IADLs (odds ratio [OR], 1.06; 95% CI, 0.99-1.14). Adjusted results were similar. However, centrally active ACE inhibitors were associated with 65% less decline in 3MSE scores per year of exposure (P = .01), and noncentrally active ACE inhibitors were associated with a greater risk of incident dementia (adjusted HR, 1.20; 95% CI, 1.00-1.43 per year of exposure) and greater odds of disability in IADLs (adjusted OR, 1.16; 95% CI, 1.03-1.30 per year of exposure) compared with other anti-HTN drugs.; Conclusions: While ACE inhibitors as a class do not appear to be independently associated with dementia risk or cognitive decline in older hypertensive adults, there may be within-class differences in regard to these outcomes. These results should be confirmed with a randomized clinical trial of a centrally active ACE inhibitor in the prevention of cognitive decline and dementia.;

Bibtex Citation

@article{Sink_2009, doi = {10.1001/archinternmed.2009.175}, url = {}, year = 2009, month = {jul}, publisher = {American Medical Association ({AMA})}, volume = {169}, number = {13}, pages = {1195}, author = {Kaycee M. Sink and Xiaoyan Leng and Jeff Williamson and Stephen B. Kritchevsky and Kristine Yaffe and Lewis Kuller and Sevil Yasar and Hal Atkinson and Mike Robbins and Bruce Psaty and David C. Goff}, title = {Angiotensin-Converting Enzyme Inhibitors and Cognitive Decline in Older Adults With Hypertension}, journal = {Arch Intern Med} }


aged, angiotensin, cognition, complications, convertting, dementia, drug effects, drug therapy, enzyme, epidemiology, etiology, female, humans, hypertension, incidence, inhibitors, male, metabolism, people, pharmacokinetics, physiology, prevention & control, prospective studies, receive, risk factors, therapeutic use, who, with

Countries of Study


Types of Dementia

Dementia (general / unspecified), Mild Cognitive Impairment (MCI)

Types of Study

Case Control Study

Type of Outcomes

ADLs/IADLs, Cognition

Type of Interventions

Risk Factor Modification

Risk Factor Modifications

General population health promotion